ERBB2 and breast cancer: Trastuzumab induces cell death through antibody-dependent cellular cytotoxicity in cells overexpressing HER2, and has revolutionized the care of breast cancer patients by demonstrated marked survival benefit in adjuvant and metastatic settings [2, 3].